Biocon Ltd. on Saturday said the U.S. health regulator has issued four observations after inspecting its Bengaluru-based active pharmaceutical ingredient facility.
ADVERTISEMENT
The US Food and Drug Administration conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.
ADVERTISEMENT
'Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time,' it added.
The company does not foresee any impact on the business, Biocon said.
RECOMMENDED FOR YOU
Dr Reddy's Hyderabad API Plant Gets Seven Observations From USFDA
Nov 19, 2024
Dr. Reddy's Labs Recalls 3.3 Lakh Bottles Of Medication In US Due To Manufacturing Issues
Nov 03, 2024
Biocon Biologics' Bengaluru Facility Receives Voluntary Action Classification From FDA
Oct 30, 2024
Britain's King Charles, Queen Camilla In Bengaluru On Three-Day Private Visit
Oct 30, 2024
POPULAR
1
Zomato's Deepinder Goyal Says Rs 20 Lakh For Chief-Of-Staff Role 'Never Part Of Plan'
2
Ukraine Says Russia Used ‘New’ Kind Of Missile As War Escalates
3
HDFC Bank To Securitise Over Rs 12,000 Crore Car Loans To Reduce Assets
4
Jharkhand Exit Poll Results 2024: Neck-And-Neck Contest Sees NDA With One Seat Edge, Independents Hold Key
5